Direkt zum Inhalt
Merck
  • Dopamine-endocannabinoid interactions mediate spike-timing-dependent potentiation in the striatum.

Dopamine-endocannabinoid interactions mediate spike-timing-dependent potentiation in the striatum.

Nature communications (2018-10-10)
Hao Xu, Sylvie Perez, Amandine Cornil, Bérangère Detraux, Ilya Prokin, Yihui Cui, Bertrand Degos, Hugues Berry, Alban de Kerchove d'Exaerde, Laurent Venance
ZUSAMMENFASSUNG

Dopamine modulates striatal synaptic plasticity, a key substrate for action selection and procedural learning. Thus, characterizing the repertoire of activity-dependent plasticity in striatum and its dependence on dopamine is of crucial importance. We recently unraveled a striatal spike-timing-dependent long-term potentiation (tLTP) mediated by endocannabinoids (eCBs) and induced with few spikes (~5-15). Whether this eCB-tLTP interacts with the dopaminergic system remains to be investigated. Here, we report that eCB-tLTP is impaired in a rodent model of Parkinson's disease and rescued by L-DOPA. Dopamine controls eCB-tLTP via dopamine type-2 receptors (D2R) located presynaptically in cortical terminals. Dopamine-endocannabinoid interactions via D2R are required for the emergence of tLTP in response to few coincident pre- and post-synaptic spikes and control eCB-plasticity by modulating the long-term potentiation (LTP)/depression (LTD) thresholds. While usually considered as a depressing synaptic function, our results show that eCBs in the presence of dopamine constitute a versatile system underlying bidirectional plasticity implicated in basal ganglia pathophysiology.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-Tyrosin-Hydroxylase-Antikörper, Klon LNC1, ascites fluid, clone LNC1, Chemicon®
Sigma-Aldrich
AM251, >98% (HPLC), solid